Briefly, treatment with the secondary metabolites of (ThCF) improves hyponatremia, hyperkalemia, and hypocalcemia in the sera of an epilepticus model, rebalances the elevated levels of many neurotransmitters, e.g., DOPA, epinephrine, norepinephrine, and glutamate, and reduces the release of GABA and acetylcholine-esterase. The gene discussed is ACHE; the disease is Hyperkalemia.